ArticleF1000Research2025
Histopathological Correlation in Suspected Celiac Disease: Linking Clinical, Serological, and Endoscopic Findings.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease (CD) is an immune-mediated enteropathy triggered by gluten in genetically susceptible individuals, characterized by villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis. Despite advances in serological testing, duodenal biopsy remains the diagnostic gold standard, especially in atypical or patchy disease. This retrospective study at King Fahd University Hospital (KFUH), Saudi Arabia, evaluated the diagnostic contribution of biopsies from the duodenal bulb (D1) and distal duodenum (D2) in 224 patients assessed for suspected CD between August 2023 and August 2024. Clinical, serological [IgA anti-tissue transglutaminase (anti-TG2), anti-endomysial antibodies (EMA), deamidated gliadin peptide], and histopathological data were analyzed. Sixty-five patients (29%) were diagnosed with CD. Villous atrophy, mucosal flattening, and increased intraepithelial lymphocytes were strongly associated with CD (p ≤ 0.001), and positive anti-TG2 and EMA correlated with Marsh grade. Combined D1 and D2 sampling improved diagnostic yield, underscoring the value of integrating histology and serology in evaluating classical and non-classical CD presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.